ACHV — Achieve Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00
- $157.90m
- $159.02m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -16.4 | -14.7 | -33.2 | -42.4 | -29.8 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 1.2 | 1.29 | 2.23 | 4.47 | 5.89 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.273 | -0.285 | 1.23 | 0.099 | -0.778 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -15.2 | -13.5 | -29.4 | -37.5 | -24.5 |
Capital Expenditures | -0.053 | -0.017 | — | — | -0.021 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 5.09 | — | — | — | — |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 5.04 | -0.017 | — | — | -0.021 |
Financing Cash Flow Items | 12.3 | 27.9 | — | 19.1 | -0.25 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 17.3 | 32.7 | 36.6 | 19.3 | 15.3 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 7.15 | 19.2 | 7.17 | -18.3 | -9.22 |